Edition:
United Kingdom

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

48.25USD
8:23pm GMT
Change (% chg)

$0.56 (+1.17%)
Prev Close
$47.69
Open
$47.52
Day's High
$50.19
Day's Low
$47.52
Volume
171,378
Avg. Vol
288,939
52-wk High
$67.10
52-wk Low
$29.54

Select another date:

Fri, Dec 22 2017

BRIEF-Portola Pharma Says FDA will extend review of AndexXa by 90 days

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION (BLA) FOR ANDEXXA® (ANDEXANET ALFA)

BRIEF-U.S. FDA Approves Prior Approval Supplement For Launch Of Portola Pharmaceuticals' Betrixaban

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES PRIOR APPROVAL SUPPLEMENT FOR COMMERCIAL LAUNCH OF PORTOLA PHARMACEUTICALS’ NOVEL ORAL ANTICOAGULANT BEVYXXA® (BETRIXABAN)

BRIEF-Portola Provides Update On European Marketing Authorization Application For Betrixaban

* PORTOLA PHARMACEUTICALS PROVIDES UPDATE ON EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR BETRIXABAN

BRIEF-Portola Pharmaceuticals provides update on Bevyxxa commercial launch

* Portola Pharmaceuticals provides update on Bevyxxa(betrixaban) commercial launch

BRIEF-Portola Pharmaceuticals appoints John Lawrence as chief medical officer

* Portola Pharmaceuticals appoints industry veteran John H. Lawrence, M.D., as senior vice president of product development and chief medical officer Source text for Eikon: Further company coverage:

BRIEF-Portola announces pricing of public offering of common stock at $55 per share

* Portola announces pricing of public offering of common stock

BRIEF-Portola Pharma announces proposed offering of common stock

* Portola Pharmaceuticals announces proposed offering of common stock

Select another date: